Nuvectis Pharma Inc. (NVCT): Price and Financial Metrics

Nuvectis Pharma Inc. (NVCT): $7.02

0.40 (-5.39%)

POWR Rating

Component Grades








NVCT Price/Volume Stats

Current price $7.02 52-week high $18.65
Prev. close $7.42 52-week low $6.20
Day low $6.85 Volume 34,900
Day high $7.56 Avg. volume 101,135
50-day MA $8.45 Dividend yield N/A
200-day MA $10.59 Market Cap 124.74M

NVCT Stock Price Chart Interactive Chart >

Nuvectis Pharma Inc. (NVCT) Company Bio

Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

NVCT Latest News Stream

Event/Time News Detail
Loading, please wait...

NVCT Latest Social Stream

Loading social stream, please wait...

View Full NVCT Social Stream

Latest NVCT News From Around the Web

Below are the latest news stories about NUVECTIS PHARMA INC that investors may wish to consider to help them evaluate NVCT as an investment opportunity.

Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma

Mitesh Borad, M.D., will serve as the Principal Investigator for the clinical trialThe Investigator-sponsored clinical trial follows the robust preclinical proof of concept data generated by investigators from Mayo Clinic in PDX models of cholangiocarcinoma (presented at the 2023 American Association for Cancer Research ("AACR"))NXP800 was granted orphan drug designation by the FDA for the treatment of cholangiocarcinoma in August 2023 Fort Lee, NJ, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pha

Yahoo | December 18, 2023

Nuvectis Pharma Insiders Added US$3.75m Of Stock To Their Holdings

Quite a few insiders have dramatically grown their holdings in Nuvectis Pharma, Inc. ( NASDAQ:NVCT ) over the past 12...

Yahoo | November 25, 2023

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Phase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing Initiated the Phase 1a Dose Escalation Study of NXP900 in Patients with Advanced Solid TumorsNXP800 Granted Orphan Drug Designation for the Treatment of CholangiocarcinomaNXP800 Phase 1a and Preclinical Data Presentations for NXP800 and NXP900 at Key Medical Conferences FORT LEE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a cli

Yahoo | November 8, 2023

Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer

Fort Lee, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced an upcoming scientific presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer (November 16-18, 2023, Boston, MA). Abstract Titles and PresentersPresentation Detai

Yahoo | October 24, 2023

We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although made...

Yahoo | October 16, 2023

Read More 'NVCT' Stories Here

NVCT Price Returns

1-mo -36.18%
3-mo N/A
6-mo -26.34%
1-year -52.37%
3-year N/A
5-year N/A
YTD -15.83%
2023 11.20%
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!